Colorectal cancer mortality 10 years after a single round of guaiac faecal occult blood test (gFOBT) screening:experiences from a Danish screening cohort by Bjerrum, Andreas et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Colorectal cancer mortality 10years after a single round of guaiac faecal occult blood
test (gFOBT) screening
Bjerrum, Andreas; Andersen, Ole; Fischer, Anders; Lindebjerg, Jan; Lynge, Elsebeth
Published in:
B M J Open Gastroenterology
DOI:
10.1136/bmjgast-2016-000120
Publication date:
2016
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Bjerrum, A., Andersen, O., Fischer, A., Lindebjerg, J., & Lynge, E. (2016). Colorectal cancer mortality 10years
after a single round of guaiac faecal occult blood test (gFOBT) screening: experiences from a Danish screening
cohort. B M J Open Gastroenterology, 3, [e000120]. https://doi.org/10.1136/bmjgast-2016-000120
Download date: 03. Feb. 2020
Colorectal cancer mortality 10 years
after a single round of guaiac faecal
occult blood test (gFOBT) screening:
experiences from a Danish screening
cohort
Andreas Bjerrum,1 Ole Andersen,1 Anders Fischer,2 Jan Lindebjerg,3
Elsebeth Lynge,1
To cite: Bjerrum A,
Andersen O, Fischer A, et al.
Colorectal cancer mortality
10 years after a single round
of guaiac faecal occult blood
test (gFOBT) screening:
experiences from a Danish
screening cohort. BMJ Open
Gastro 2016;3:e000120.
doi:10.1136/bmjgast-2016-
000120
Received 1 September 2016
Revised 3 October 2016
Accepted 18 October 2016
1Department of Public Health,
University of Copenhagen,
Copenhagen K, Denmark
2Copenhagen University
Hospital Herlev, Herlev,
Denmark
3Department of Pathology,
Vejle Hospital, Vejle,
Denmark
Correspondence to
Dr Andreas Bjerrum;
ab@medicinsk.dk
ABSTRACT
Background: In Denmark, colorectal cancer (CRC) is
the third most frequent cancer. Randomised trials have
shown that guaiac faecal occult blood test (gFOBT)
screening can reduce CRC mortality, but a recent large
randomised study from Finland did not find any effect.
A feasibility study was carried out in Denmark in
2005–2006 where residents aged 50–74 years in 2
Danish counties were invited once to participate in
gFOBT screening. We used the unique Danish registers
to assess the impact of gFOBT screening in this group
on CRC incidence and mortality.
Methods: In this cohort study, we followed a group
comprising 166 277 individuals invited to screening
and a reference group comprising the remaining
1 240 348 Danes of the same age. We linked the
Danish population and health service registers to
obtain information about colonoscopies,
polypectomies, incident CRC and cause of death.
Results: After a median follow-up time of 8.9 years,
the CRC mortality was significantly lower in the
screening group than in the reference group with an
adjusted HR (aHR) of 0.92 (95% CI 0.86 to 0.99),
while the aHR for all-cause mortality was 0.95 (95% CI
0.94 to 0.96). For screening participants, the aHR for
CRC mortality and all-cause mortality was 0.72 (0.64
to 0.80) and 0.59 (0.57 to 0.60), respectively.
Conclusions: About 10 years after a single round of
gFOBT screening, we found a significant 8% deficit in
CRC mortality in the screening group compared with
other Danes. We found almost the same deficit in all-
cause mortality, and on this basis, it is not possible to
conclude that one screening round had an effect on
CRC mortality. Our study indicated that close monitoring
of the outcome of CRC screening is warranted.
INTRODUCTION
In Denmark, colorectal cancer (CRC) is the
third most frequent cancer for men and
women aged 50–74 years with age-standardised
incidences of 160 and 126 cases per 100 000
(Nordic Standard Population, 2007–2011).1
Several randomised trials have shown that
guaiac faecal occult blood test (gFOBT)
screening can reduce CRC mortality2–5 and
CRC screening has been implemented in
several countries to detect and treat CRC
before the disease becomes symptomatic.
In a recent large randomised study from
Finland, Pitkäniemi et al6 did not detect any
effect of gFOBT screening on CRC mortality.
Summary box
What is already known about this subject?
▸ Randomised controlled trials with faecal occult
blood based screening have shown a reduction
in colorectal cancer mortality.
▸ Based on the favourable outcomes, colorectal
cancer screening is now widely implemented.
▸ However, no reduction in colorectal cancer mor-
tality was found in a large Finnish randomised
health service study, though with a relatively
short follow-up time.
What are the new findings?
▸ We report long term follow-up from a Danish
screening feasibility study including one round
of faecal occult blood based screening.
▸ The population invited to screening had an 8%
lower colorectal cancer mortality and a 5% lower
all-cause mortality as compared with other
Danes.
▸ As the deficits in colorectal cancer and all-cause
mortality were almost equal, it is not possible to
conclude that one screening round had an effect
on colorectal cancer mortality.
How might it impact on clinical practice in
the foreseeable future?
▸ Our study indicates that close monitoring of the
outcome of colorectal cancer screening is
warranted.
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In contrast to the previous randomised trials,7 the
Finnish study was designed as a randomised health
service study embedded in the routine health services
and the authors argued that this was characterised by
variation in available resources; a population that may
have been less motivated; and health experts that were
possibly not as devoted and did not follow guidelines as
strictly as in scientiﬁc trials.6
As an input to the Danish debate on a possible national
CRC screening programme, a feasibility study within the
routine healthcare was carried out in 2005–2006.8 9
Residents aged 50–74 years in two Danish counties were
invited once to participate in the screening performed
with gFOBT. Colonoscopy or alternatively colonography
was offered if the screening test was positive. From 1
January 2014, a nationwide screening programme was
implemented in Denmark following the same scheme,
but based on the faecal immunochemical test (FIT).
The unique Danish population and health registers
allowed us to follow-up the population invited for the
feasibility study for 10 years to assess the impact of the
screening on CRC incidence and mortality in a routine
healthcare setting.
METHODS
Study design and study population
In this population-based cohort-study, we included all
Danish residents born between 3 August 1930 and 2
August 1955 and living in Denmark on 2 August 2005.
The screening group comprised persons invited to CRC
screening, that is, all inhabitants in Vejle county and a
random sample of approximately half of the inhabitants
in the Copenhagen county, while the reference group
comprised the other Danes.
Individual invitation dates were known for the screen-
ing group. We used the invitation scheme from the
screening group to assign pseudoinvitation dates to
persons in the reference group. In the following, we use
the term ‘invitation date’ for the ‘true invitation dates’
in the screening group and ‘pseudoinvitation dates’ in
the reference group.
Based on unique personal identiﬁcation, we linked
each person with the Danish Cancer Register to obtain
information about incident CRC cases, the National
Patient Register for diagnoses and hospital procedures
including colonoscopies and polypectomies, the Health
Service Register for private sector colonoscopies and
polypectomies, and the Death Cause Register.
We excluded persons who died or emigrated before
the invitation date, were diagnosed with CRC (ICD10:
C18/C19/C20/C21) or inﬂammatory bowel disease
(ICD8: 563.01/563.02/563.09/563.19 and ICD10: K50/
K51) prior to invitation; or persons who underwent col-
onoscopy, sigmoidoscopy or any invasive colon or ano-
rectal procedure in the period from 2 years before the
screening programme started, that is, 2 August 2003,
until the invitation date. Data linkage identiﬁed a
number of persons excluded from screening for
unknown reasons. These persons were excluded from
the screening group in our analyses. We performed sen-
sitivity analyses to assess the impact of this group on our
results.
Screening process
Persons invited to the screening programme received a
gFOBT kit per mail. The letter included an invitation
describing the background and purpose of screening,
instructions for sampling and a prepaid return envelope.
Participants with a positive gFOBT were notiﬁed by
mail and invited to colonoscopy or alternatively
colonography.
In Vejle County, colonoscopies were performed at
three selected hospitals. Diagnostic biopsy and polypect-
omy was performed as part of the follow-up procedure.
In Copenhagen County, colonoscopies were performed
in hospitals and private clinics. Patients with many aden-
omas were referred to hospitals for further diagnostic
procedures and polypectomy. Postpolypectomy surveil-
lance was not speciﬁed in the feasibility study, but under-
taken according to the clinical practice at the respective
hospitals.
Definitions and statistical analyses
Persons were followed from the invitation date to date of
death, emigration or 31 December 2014, whichever
came ﬁrst. The ﬁrst colonoscopy performed after a posi-
tive gFOBT was deﬁned as the baseline colonoscopy, as
Figure 1 Inclusion and exclusion in the study population.1 The same person may fall for more than one criterion for exclusion.
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long as it was within 90 days of invitation. CRC-cases
diagnosed within 180 days after the baseline colonoscopy
were categorised as screen-detected CRC.
We calculated incidence-based CRC mortality rates
for the screening and reference groups, including only
CRC deaths in cases diagnosed after the invitation
date. The multivariate Cox regression was used to cal-
culate HRs adjusted for sex and age (aHR) for CRC
incidence, CRC mortality and all-cause mortality.
Gender-based analyses were adjusted for age, and
persons in the screening group were compared with
persons in the reference group of the same gender. We
tested for interactions and proportionality based on
Schoenfeld residuals.
We estimated the excess mortality rate by dividing the
excess number of deaths observed in persons with CRC
by the total number of person-years in the screening
group and reference group (stratiﬁed by sex and age).
The excess mortality rate ratio was calculated according
to procedures described by van Leeuwen et al.10
All statistical analyses were conducted with Stata
V.14.1.
Ethics
The Danish Data Protection Agency approved the
linkage between the registers in this study ( J.-no.
2015-41-4012). The study was not subject to approval by
the Ethics Committee since data collection did not
involve patient contact or access to patients’ medical
records.
RESULTS
We identiﬁed 1 524 259 persons aged 50–74 years and
living in Denmark on 2 August 2005. A total of 117 634
persons were excluded based on predeﬁned criteria
(ﬁgure 1). Consequently, this study included 1 406 625
persons divided into the screening group of 166 277,
and a reference group of 1 240 348. The median
follow-up time was 8.9 years for the screening group and
Table 1 Characteristics of the study population
Screening
group
Reference
group
p
Value
Population 166 277 1 240 348
Person time
(years)
1 393 131 10 358 902
Sex
Female 48.9% 49.5% <0.01
Male 51.1% 50.5%
Median age at
invitation
60.6 60.5 0.06
50−54 years 21.8% 22.0% 0.10
55−59 years 25.2% 25.4% 0.08
60−64 years 22.9% 22.8% 0.24
65−69 years 16.7% 16.3% <0.01
70−74 years 13.0% 12.8% <0.01
74+ years 0.4% 0.8% <0.01
The screening group includes persons invited to colorectal cancer
screening in Vejle and Copenhagen counties. The reference group
includes persons in the rest of Denmark in the same age group.
Table 2 Comparison between the screening group from Vejle and Copenhagen counties and the intervention group from the
randomised controlled trial in Funen, Denmark5
Screening group Vejle and
Copenhagen counties
Intervention group, randomised
controlled trial, Funen, Denmark
Number % of group above Number % of group above
Number invited 166 277 NR 30 970 NR
Participants 80 563 48.5% 20 672 66.7%
Positive FOBT 1924 2.4% 215 1.0%
Colonoscopy 1741 90.5% 203 94.4%
Colorectal cancer 155 8.9% 37 18.2%
Table 3 Percentage and number of persons with colonoscopies and polypectomy
Screening group Reference group
No. Percentage* No. Percentage†
Persons with colonoscopy 30 264 18.2 206 125 16.7
Persons with colonoscopy≤2 years from invitation 7513 4.5 42 886 3.5
Persons with colonoscopy >2 years from invitation 25 432 15.3 179 282 14.5
Persons with polypectomy 7157 4.3 46 383 3.7
Persons with polypectomy ≤2 years from invitation 1808 1.1 8391 0.7
Persons with polypectomy >2 years from invitation 5656 3.4 39 364 3.2
*Percentage of 166 277 persons in the screening group.
†Percentage of 1 240 348 persons in the reference group.
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the reference group with an IQR of 208 and 210 days for
the screening group and reference group, respectively.
The longest follow-up was 9.4 years in both groups.
The proportion of women was marginally lower in the
screening group than in the reference group (table 1).
Moreover, in the screening group, there was a small but
signiﬁcant over-representation of persons aged 65–
74 years, and a marginally smaller proportion of persons
aged 75 years and above.
In the screening group, 80 563 persons (48.5%)
returned a stool sample. Among those, 1924 (2.4%) had
a positive gFOBT, of whom 1737 (90.3%) underwent col-
onoscopy. Among those, 155 (8.9%) patients were diag-
nosed with CRC (table 2). About 4.5% in the screening
group underwent colonoscopy within the ﬁrst 2 years
after invitation compared with 3.5% in the reference
group (table 3). More than 2 years after the invitation,
the two groups had almost the same use of colonos-
copies. Polypectomy was performed in 4.3% of the
screening group compared with 3.7% in the reference
group. Within the ﬁrst 2 years after invitation, 1.1% from
the screening group underwent polypectomy compared
with 0.7% in the reference group.
The CRC incidence during the follow-up period was
signiﬁcantly lower in the screening group than in
the reference group (aHR 0.94, 95% CI 0.90 to 0.97)
(table 4). In the screening group, CRC incidence rose
quickly within the ﬁrst year after invitation due to
screen-detected cases. After ∼3.5 years, the curve for the
screening group crossed the curve for the reference
group (ﬁgure 2).
The CRC mortality during the follow-up period was
signiﬁcantly lower in the screening group than in the
reference group (aHR 0.92, 95% CI 0.86 to 0.99), with
the deﬁcit coming from the Copenhagen part of the
screening group (aHR for Vejle 0.96, 95% CI 0.87 to
1.06; aHR for Copenhagen 0.89, 95% CI 0.80 to 0.98)
(table 4). We did not observe any difference between
men and women. The all-cause mortality was also
signiﬁcantly lower in the screening group than in the
reference group (aHR 0.95, 95% CI 0.94 to 0.96), with
the deﬁcit coming from Vejle county (aHR for Vejle
0.91, 95% CI 0.90 to 0.93; aHR for Copenhagen 1.00,
95% CI 0.98 to 1.02). The deﬁcit in Vejle was seen
from the very beginning of the follow-up period
(ﬁgure 3).
Perprotocol analysis showed that screening partici-
pants had lower CRC incidence (aHR 0.94, 95% CI 0.90
to 0.97), lower CRC mortality (aHR 0.72, 95% CI 0.64 to
0.80) and substantially lower all-cause mortality (aHR
0.59, 95% CI 0.57 to 0.60) (table 4). Non-responders
had signiﬁcantly increased CRC mortality (aHR of 1.12,
95% CI 1.03 to 1.23) and all-cause mortality (aHR 1.31,
95% CI 1.29 to 1.33).
The excess mortality rate ratio due to CRC for the
screening group was 0.93 (95% CI 0.84 to 1.02); 0.93
(95% CI 0.82 to 1.07) for Vejle County and 0.92 (95%
CI 0.80 to 1.06) for Copenhagen County.
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Sensitivity analyses to assess the inﬂuence of 3757
persons, who were excluded from screening in the feasi-
bility study for unknown reasons, showed that their
inclusion in the analyses did not inﬂuence our results
signiﬁcantly (data not shown).
DISCUSSION
Approximately 10 years after a single round of gFOBT
screening for CRC, we found a signiﬁcant 8% lower
incidence-based CRC mortality in the invited screening
group than in the reference group of other Danes. This
could point to a beneﬁcial impact of the screening. It
should, however, be taken into account that the invited
screening group did not represent a random sample of
the Danish population. The all-cause mortality was 5%
lower in the invited screening group than in the refer-
ence group. As the difference in the deﬁcits of 8% for
CRC mortality and 5% for all-cause mortality is mar-
ginal, it is not possible to attribute the reduced CRC
mortality to one screening round alone. The uncertainty
in these numbers came from the Vejle part of the
invited screening group, as this group clearly repre-
sented a healthier subpopulation than the rest of Danes.
One may argue that the Copenhagen part of the invited
screening group would give a clearer picture of the
screening effect as this group had a 11% deﬁcit in CRC
mortality and an all-cause mortality similar to that of
other Danes. This is, however, a subgroup analysis not
originally planned for.
Figure 2 Cumulative colorectal cancer incidence in persons
from Vejle and Copenhagen counties invited to screening and
in persons from the rest of Denmark.
Figure 3 Cumulative colorectal cancer mortality and all-cause mortality in persons in Vejle and Copenhagen counties invited to
screening and in persons in the rest of Denmark.
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Screening participants represented a selected group.
When compared with the reference group, participants
had a 41% lower all-cause mortality, while non-
participants had a 31% higher all-cause mortality. This
highlights the problem of inequitable uptake of screen-
ing services; those who participate are healthier than
those who do not. Since we could not control for select-
ive participation in the HRs for CRC mortality, the
reported deﬁcit in CRC mortality among participants
should be interpreted with caution.
When compared with the earlier randomised con-
trolled trial on gFOBT CRC screening in Funen,
Denmark, the participation in the feasibility study was
low, 49% when compared with 67%, though the CRC
detection rates were identical, 1.9 per 1000 participants
in the feasibility study and 1.8 in the trial.5 Within the
group invited to screening, 18% had at least one colon-
oscopy during the ∼10 years of follow-up. Colonoscopy
rate was higher in the screening group within the ﬁrst
2 years, but equal to ﬁndings in the reference group the
following years. This may be due to cancer awareness
within the general population and among general practi-
tioners in Denmark.
The screen-detected cases represented only 155 out of
the 2794 CRC cases in the group invited to screening.
The remaining 2639 CRC cases were detected within
the routine healthcare system with prognosis compar-
able to cases detected in the reference group. The poly-
pectomy rate within the ﬁrst 2 years after invitation was
higher in the screening group than in the reference
group. Colorectal adenomas may be cancer precursors,11
and there is evidence that detection and removal of
these lesions may prevent cancers.12 This is expected to
have contributed to the slightly lower CRC incidence in
the screening group than in the reference group; 2794
observed cases vs 2972 (=2794/0.94 aHR for CRC inci-
dence) expected cases, resulting in a deﬁcit of 178
cases. The potential effect of the one-round screening
on the CRC mortality was therefore based on the rela-
tively few cases detected at screening or prevented
due to polypectomy. This ﬁnding clearly illustrates the
need for repeated testing in faecal occult blood-based
screening programmes.
van Leeuwen et al10 have shown that, in prostate
cancer screening, disease-speciﬁc mortality has been
systematically underestimated due to risk of misclassiﬁca-
tion of cause-of-death. The authors argue that estimation
of the excess mortality is of additional value to a disease-
speciﬁc mortality analysis since it measures the effect of
screening in the presence of all competing risks. We did
not notice any discrepancy between disease-speciﬁc mor-
tality and excess mortality in our data, which indicates
high data quality and accuracy.
It was a strength of this study that we could individu-
ally follow all persons invited to screening in 2005/2006
for a period of ∼10 years. It was furthermore a strength
that linkage to the Danish Cancer Register allowed us to
calculate incidence-based CRC mortality. It was a
weakness of this observational study that we were not
able to control for prescreening differences in health
status between the screening counties and the rest of
Denmark. This is in contrast to the Danish studies on
the effect of mammography screening on breast cancer
mortality,13 14 where calendar period and region were
controlled for in the analysis. The study relied on health
service register data submitted by health providers.
While the quality of register data is considered to be
high,15 we did encounter some discrepancies in the
register data on colonoscopies and polypectomies,
which may have introduced bias.
Biennial gFOBT CRC screening has been introduced
in many countries based on the results from the rando-
mised controlled trials in Minnesota,2 Göteborg,3
Nottingham4 and Funen.5 A systematic review from the
US Preventive Services Task Force showed a signiﬁcant
reduction in CRC mortality after 11–30 years (relative
risk (RR) 0.91, 95% CI 0.84 to 0.98) and after 30 years
(RR 0.78, 95% CI 0.65 to 0.93).7 A Finnish population-
based gFOBT CRC screening programme was intro-
duced as a public health trial, where a random 50% of
each birth cohort was invited.6 The results of the
Finnish study were too new to be included in the US sys-
tematic review. However, after accumulation of 180 000
persons invited to screening, and with a follow-up of on
average 4.5 years, there was no impact of the screening
on CRC mortality (RR 1.04, 95% CI 0.84 to 1.28).6 In
contrast to the Finnish study, we did not observe any dif-
ference in screening effect between men and women. A
4.5 average years of follow-up is a short time, but the
Finnish results, together with the more limited data
from this Danish feasibility study, nevertheless indicate
that close monitoring of the outcome of the ongoing
CRC screening programmes is warranted. The combined
effect of increased cancer awareness, good access to col-
onoscopy and accelerated cancer care pathways may
improve early detection and treatment for CRC and
diminish the potential impact of gFOBT screening. The
FIT is more acceptable for participants than the gFOBT,
and it also has higher sensitivity for faecal blood.16 17
For this reason, many countries, including Denmark,
now use FIT in their CRC screening programmes.
CONCLUSION
An ∼10 years’ follow-up of a one-round CRC screening
in a Danish feasibility study showed an 8% deﬁcit in
CRC mortality when compared with Danes in the rest of
the country. There was however almost the same deﬁcit
in the all-cause mortality. On this basis, it is not possible
to conclude that screening in the feasibility study had an
effect on CRC mortality. Our results, together with new
results from the large Finnish CRC screening pro-
gramme, indicate that close monitoring of the outcome
of CRC screening programmes is warranted.
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